CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial

Open access
Feig, Denice S, Donovan, Lois E, Corcoy, Rosa, Murphy, Kellie E, Amiel, Stephanie A, Hunt, Katharine F, Asztalos, Elizabeth, Barrett, Jon F R, Sanchez, J Johanna, de Leiva, Alberto, Hod, Moshe, Jovanovic, Lois, Keely, Erin, McManus, Ruth, Hutton, Eileen K, Meek, Claire L, Stewart, Zoe A, Wysocki, Tim, O'Brien, Robert, Ruedy, Katrina, Kollman, Craig, Tomlinson, George, Murphy, Helen R, Grisoni, Jeannie, Byrne, Carolyn, Davenport, Katy, Neoh, Sandra, Gougeon, Claire, Oldford, Carolyn, Young, Catherine, Green, Louisa, Rossi, Benedetta, Rogers, Helen, Cleave, Barbara, Strom, Michelle, Adelantado, Juan María, Isabel Chico, Ana, Tundidor, Diana, Malcolm, Janine, Henry, Kathy, Morris, Damian, Rayman, Gerry, Fowler, Duncan, Mitchell, Susan, Rosier, Josephine, Temple, Rosemary, Turner, Jeremy, Canciani, Gioia, Hewapathirana, Niranjala, Piper, Leanne, Kudirka, Anne, Watson, Margaret, Bonomo, Matteo, Pintaudi, Basilio, Bertuzzi, Federico, Daniela, Giuseppina, Mion, Elena, Lowe, Julia, Halperin, Ilana, Rogowsky, Anna, Adib, Sapida, Lindsay, Robert, Carty, David, Crawford, Isobel, Mackenzie, Fiona, McSorley, Therese, Booth, John, McInnes, Natalia, Smith, Ada, Stanton, Irene, Tazzeo, Tracy, Weisnagel, John, Mansell, Peter, Jones, Nia, Babington, Gayna, Spick, Dawn, MacDougall, Malcolm, Chilton, Sharon, Cutts, Terri, Perkins, Michelle, Scott, Eleanor, Endersby, Del, Dover, Anna, Dougherty, Frances, Johnston, Susan, Heller, Simon, Novodorsky, Peter, Hudson, Sue, Nisbet, Chloe, Ransom, Thomas, Coolen, Jill, Baxendale, Darlene, Holt, Richard, Forbes, Jane, Martin, Nicki, Walbridge, Fiona, Dunne, Fidelma, Conway, Sharon, Egan, Aoife, Kirwin, Collette, Maresh, Michael, Kearney, Gretta, Morris, Juliet, Quinn, Susan, Bilous, Rudy, Mukhtar, Rasha, Godbout, Ariane, Daigle, Sylvie, Lubina, Alexandra, Jackson, Margaret, Paul, Emma, Taylor, Julie, Houlden, Robyn, Breen, Adriana, Banerjee, Anita, Brackenridge, Anna, Briley, Annette, Reid, Anna, Singh, Claire, Newstead-Angel, Jill, Baxter, Janet, Philip, Sam, Chlost, Martyna, Murray, Lynne, Castorino, Kristin, Frase, Donna, Lou, Olivia, Pragnell, Marlon · 2017 · The Lancet

Abstract

Background Pregnant women with type 1 diabetes are a high-risk population who are recommended to strive for optimal glucose control, but neonatal outcomes attributed to maternal hyperglycaemia remain suboptimal. Our aim was to examine the effectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neonatal health outcomes. Methods In this multicentre, open-label, randomised controlled trial, we recruited women aged 18–40 years with type 1 diabetes for a minimum of 12 months who were receiving intensive insulin therapy. Participants were pregnant (≤13 weeks and 6 days' gestation) or planning pregnancy from 31 hospitals in Canada, England, Scotland, Spain, Italy, Ireland, and the USA. We ran two trials in parallel for pregnant participants and for participants planning pregnancy. In both trials, participants were randomly assigned to either CGM in addition to capillary glucose monitoring or capillary glucose monitoring alone. Randomisation was stratified by insulin delivery (pump or injections) and baseline glycated haemoglobin (HbA 1c ). The primary outcome was change in HbA 1c from randomisation to 34 weeks' gestation in pregnant women and to 24 weeks or conception in women planning pregnancy, and was assessed in all randomised participants with baseline assessments. Secondary outcomes included obstetric and neonatal health outcomes, assessed with all available data without imputation. This trial is registered with ClinicalTrials.gov, number NCT01788527. Findings Between March 25, 2013, and March 22, 2016, we randomly assigned 325 women (215 pregnant, 110 planning pregnancy) to capillary glucose monitoring with CGM (108 pregnant and 53 planning pregnancy) or without (107 pregnant and 57 planning pregnancy). We found a small difference in HbA 1c in pregnant women using CGM (mean difference −0·19%; 95% CI −0·34 to −0·03; p=0·0207). Pregnant CGM users spent more time in target (68% vs 61%; p=0·0034) and less time hyperglycaemic (27% vs 32%; p=0·0279) than did pregnant control participants, with comparable severe hypoglycaemia episodes (18 CGM and 21 control) and time spent hypoglycaemic (3% vs 4%; p=0·10). Neonatal health outcomes were significantly improved, with lower incidence of large for gestational age (odds ratio 0·51, 95% CI 0·28 to 0·90; p=0·0210), fewer neonatal intensive care admissions lasting more than 24 h (0·48; 0·26 to 0·86; p=0·0157), fewer incidences of neonatal hypoglycaemia (0·45; 0·22 to 0·89; p=0·0250), and 1-day shorter length of hospital stay (p=0·0091). We found no apparent benefit of CGM in women planning pregnancy. Adverse events occurred in 51 (48%) of CGM participants and 43 (40%) of control participants in the pregnancy trial, and in 12 (27%) of CGM participants and 21 (37%) of control participants in the planning pregnancy trial. Serious adverse events occurred in 13 (6%) participants in the pregnancy trial (eight [7%] CGM, five [5%] control) and in three (3%) participants in the planning pregnancy trial (two [4%] CGM and one [2%] control). The most common adverse events were skin reactions occurring in 49 (48%) of 103 CGM participants and eight (8%) of 104 control participants during pregnancy and in 23 (44%) of 52 CGM participants and five (9%) of 57 control participants in the planning pregnancy trial. The most common serious adverse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three participants planning pregnancy). Interpretation Use of CGM during pregnancy in patients with type 1 diabetes is associated with improved neonatal outcomes, which are likely to be attributed to reduced exposure to maternal hyperglycaemia. CGM should be offered to all pregnant women with type 1 diabetes using intensive insulin therapy. This study is the first to indicate potential for improvements in non-glycaemic health outcomes from CGM use. Funding Juvenile Diabetes Research Foundation, Canadian Clinical Trials Network, and National Institute for Health Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)32400-5

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile for (A) participants in the pregnancy trial and (B) participants in the planning pregnancy trial CGM=continuous glucose monitoring. HbA1c= glycated haemoglobin. *Central laboratory HbA1c data were not available at randomisation for nine CGM group participants (six lost or not collected, two withdrawals, and one pregnancy loss) and 11 control group participants (nine lost or not collected, one withdrawal, and one pregnancy loss) and not available for an additional ten participants in the CGM group and 12 participants in the control group at 34 weeks. †CGM data unavailable. CGM data were available for 77 CGM participants using real-time sensor and 77 control group participants using an iPro2 masked sensor. ‡Central laboratory HbA1c measurements were not available for eight participants in the CGM group (five lost or not collected and three withdrawals) and six control group participants (five lost or not collected and one withdrawal). §CGM data not available. CGM data were available for 39 CGM participants using real-time sensor and 52 control group participants using an iPro2 masked sensor.
Figure 1 Trial profile for (A) participants in the pregnancy trial and (B) participants in the planning pregnancy trial CGM=continuous glucose monitoring. HbA1c= glycated haemoglobin. *Central laboratory HbA1c data were not available at randomisation for nine CGM group participants (six lost or not collected, two withdrawals, and one pregnancy loss) and 11 control group participants (nine lost or not collected, one withdrawal, and one pregnancy loss) and not available for an additional ten participants in the CGM group and 12 participants in the control group at 34 weeks. †CGM data unavailable. CGM data were available for 77 CGM participants using real-time sensor and 77 control group participants using an iPro2 masked sensor. ‡Central laboratory HbA1c measurements were not available for eight participants in the CGM group (five lost or not collected and three withdrawals) and six control group participants (five lost or not collected and one withdrawal). §CGM data not available. CGM data were available for 39 CGM participants using real-time sensor and 52 control group participants using an iPro2 masked sensor.CC BY · PubMed Central
Figure 2 Primary glycaemic outcome showing participants' HbA1c levels according to pregnancy status Mean HbA1c (95% CI) is shown at each assessment time for participants who had data at baseline and the time of the outcome assessment (24 and 34 weeks' gestation in the pregnancy trial and at 12 and 24 weeks from randomisation or at time of confirmed pregnancy in the pregnancy planning trial). Data are also shown for participants in the planning pregnancy trial who conceived before 24 weeks and stayed in the trial during pregnancy. CGM=continuous glucose monitoring. HbA1c=glycated haemoglobin.
Figure 2 Primary glycaemic outcome showing participants' HbA1c levels according to pregnancy status Mean HbA1c (95% CI) is shown at each assessment time for participants who had data at baseline and the time of the outcome assessment (24 and 34 weeks' gestation in the pregnancy trial and at 12 and 24 weeks from randomisation or at time of confirmed pregnancy in the pregnancy planning trial). Data are also shown for participants in the planning pregnancy trial who conceived before 24 weeks and stayed in the trial during pregnancy. CGM=continuous glucose monitoring. HbA1c=glycated haemoglobin.CC BY · PubMed Central
Figure 3 Neonatal outcomes of pregnancy trial participants (A) Neonatal birthweight centiles are shown with box plots. The horizontal line in the middle of each box represents the median, and the lower and upper boundaries of the box represent the 25th and 75th percentiles, respectively. Whiskers are drawn to the smallest value that is within 1·5 × IQR below the 25th percentile. Values outside of the whiskers are drawn individually. These data are based on customised growth charts (gestation-related optimal weight) that adjust infant birthweight for maternal parity, ethnicity, height, and weight, and for infant sex and gestational age.20 (B) The Kaplan-Meier plot shows infants' length of hospital stay from delivery until hospital discharge.
Figure 3 Neonatal outcomes of pregnancy trial participants (A) Neonatal birthweight centiles are shown with box plots. The horizontal line in the middle of each box represents the median, and the lower and upper boundaries of the box represent the 25th and 75th percentiles, respectively. Whiskers are drawn to the smallest value that is within 1·5 × IQR below the 25th percentile. Values outside of the whiskers are drawn individually. These data are based on customised growth charts (gestation-related optimal weight) that adjust infant birthweight for maternal parity, ethnicity, height, and weight, and for infant sex and gestational age.20 (B) The Kaplan-Meier plot shows infants' length of hospital stay from delivery until hospital discharge.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. van Buuren, 2011, Multivariate imputation by chained equations in R, J Stat Softw, 45, 1

Cited by

See all 911

Metadata

Authors
Feig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., Hod, M., Jovanovic, L., Keely, E., McManus, R., Hutton, E. K., Meek, C. L., Stewart, Z. A., Wysocki, T., O'Brien, R., Ruedy, K., Kollman, C., Tomlinson, G., Murphy, H. R., Grisoni, J., Byrne, C., Davenport, K., Neoh, S., Gougeon, C., Oldford, C., Young, C., Green, L., Rossi, B., Rogers, H., Cleave, B., Strom, M., Adelantado, J. M., Isabel Chico, A., Tundidor, D., Malcolm, J., Henry, K., Morris, D., Rayman, G., Fowler, D., Mitchell, S., Rosier, J., Temple, R., Turner, J., Canciani, G., Hewapathirana, N., Piper, L., Kudirka, A., Watson, M., Bonomo, M., Pintaudi, B., Bertuzzi, F., Daniela, G., Mion, E., Lowe, J., Halperin, I., Rogowsky, A., Adib, S., Lindsay, R., Carty, D., Crawford, I., Mackenzie, F., McSorley, T., Booth, J., McInnes, N., Smith, A., Stanton, I., Tazzeo, T., Weisnagel, J., Mansell, P., Jones, N., Babington, G., Spick, D., MacDougall, M., Chilton, S., Cutts, T., Perkins, M., Scott, E., Endersby, D., Dover, A., Dougherty, F., Johnston, S., Heller, S., Novodorsky, P., Hudson, S., Nisbet, C., Ransom, T., Coolen, J., Baxendale, D., Holt, R., Forbes, J., Martin, N., Walbridge, F., Dunne, F., Conway, S., Egan, A., Kirwin, C., Maresh, M., Kearney, G., Morris, J., Quinn, S., Bilous, R., Mukhtar, R., Godbout, A., Daigle, S., Lubina, A., Jackson, M., Paul, E., Taylor, J., Houlden, R., Breen, A., Banerjee, A., Brackenridge, A., Briley, A., Reid, A., Singh, C., Newstead-Angel, J., Baxter, J., Philip, S., Chlost, M., Murray, L., Castorino, K., Frase, D., Lou, O., & Pragnell, M.
Affiliations
  • University of Toronto (CA)
  • University of Calgary (CA)
  • Hospital de Sant Pau (ES)
  • King's College London (GB)
  • Sunnybrook Hospital (CA)
  • Rabin Medical Center (IL)
  • University of Ottawa (CA)
  • Western University (CA)
  • McMaster University (CA)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Nemours Children's Health System (US)
  • Jaeb Center for Health Research (US)
  • University Health Network (CA)
  • University of East Anglia (GB)
Corresponding author
Feig, Denice S
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-11
Volume
390
Issue
10110
Pages
2347-2359
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2755734682
Cited by
803
References
34
Citations by year
2026: 87 · 2025: 110 · 2024: 119 · 2023: 102 · 2022: 80 · 2021: 93 · 2020: 71 · 2019: 68 · 2018: 62 · 2017: 8
FWCI
67.29
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Leicester Research Archive (University of Leicester) (submittedVersion, cc-by-nc-nd)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Sunnybrook Research Institute
  • National Institute for Health and Care Research (ACF-2016-14-009, CDF-2013-06-035, 2013-06-035)
  • University of Cambridge
  • Cambridge University Hospitals
  • Tommy's
  • FedDev Ontario
  • Breakthrough T1D Canada (17-2012-383)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
continuous glucose monitoring, type 1 diabetes in pregnancy, HbA1c, maternal glucose control, intensive insulin therapy, neonatal outcomes, obstetric outcomes, preconception care, time in target glucose range, hypoglycemia, maternal hyperglycemia
MeSH terms
Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Insulin, Monitoring, Physiologic, Pregnancy, Pregnancy Outcome, Severity of Illness Index, Observer Variation, Odds Ratio, Risk Assessment, Internationality, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)32400-5
The paper
Feig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., Hod, M., Jovanovic, L., Keely, E., McManus, R., Hutton, E. K., Meek, C. L., Stewart, Z. A., Wysocki, T., O'Brien, R., . . . Pragnell, M. (2017). Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)32400-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.